Wells Fargo
CADL icon

Wells Fargo’s Candel Therapeutics CADL Stock Holding History

Wells Fargo’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.3K Sell
16,593
-57,306
-78% -$312K ﹤0.01% 5218
2025
Q4 		$418K Buy
73,899
+47,588
+181% +$256K ﹤0.01% 4622
2025
Q3 		$134K Buy
26,311
+5,536
+27% +$32K ﹤0.01% 5159
2025
Q2 		$105K Buy
20,775
+7,186
+53% +$37K ﹤0.01% 5168
2025
Q1 		$76.8K Buy
13,589
+3,467
+34% +$28.3K ﹤0.01% 5229
2024
Q4 		$87.9K Buy
10,122
+3,935
+64% +$23.3K ﹤0.01% 5269
2024
Q3 		$42.9K Sell
6,187
-157
-2% -$975 ﹤0.01% 5401
2024
Q2 		$39.3K Buy
6,344
+6,229
+5,417% +$46.7K ﹤0.01% 5385
2024
Q1 		$182 Buy
115
+2
+2% +$3 ﹤0.01% 6512
2023
Q4 		$166 Buy
113
+5
+5% +$5 ﹤0.01% 6652
2023
Q3 		$99 Buy
108
+4
+4% +$5 ﹤0.01% 6775
2023
Q2 		$131 Buy
104
+4
+4% +$6 ﹤0.01% 6811
2023
Q1 		$135 Buy
100
+2
+2% +$4 ﹤0.01% 6871
2022
Q4 		$175 Buy
98
+2
+2% +$4 ﹤0.01% 6654
2022
Q3 		$0 Buy
96
+35
+57% +$119 ﹤0.01% 6700
2022
Q2 		$0 Buy
+61
New +$244 ﹤0.01% 6839
2021
Q4 		– Sell
-1,054
Closed -$12K – 7248
2021
Q3 		$12K Buy
+1,054
New +$8.74K ﹤0.01% 6145

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's CADL Position: Q1 2026 in Review

Wells Fargo reduced its Candel Therapeutics (CADL) stake by 78% in Q1 2026, selling an estimated $312K and leaving 16,593 shares worth $81.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5218.

Wells Fargo first reported a position in CADL in Q3 2021 and has held it in 17 quarters since. The position peaked at $418K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Wells Fargo held 16,593 shares of Candel Therapeutics worth $81.3K as of Q1 2026.
  • Wells Fargo sold 57,306 Candel Therapeutics shares in Q1 2026, an estimated $312K.
  • Candel Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5218 holding.
  • Wells Fargo first reported a position in Candel Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • Wells Fargo's Candel Therapeutics position peaked at $418K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.